ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. Leading healthcare companies have licensed rights to use ImmunoGen's technology to develop novel anticancer therapies, and Roche's marketed product, Kadcyla, utilizes ImmunoGen's ADC technology.
Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
308 (est)-2%
ImmunoGen was founded in 1981 and is headquartered in Waltham, US

Key People at ImmunoGen

Daniel M. Junius

Daniel M. Junius

President & CEO
Stephen C. McCluski

Stephen C. McCluski

Chairman
Gregory D. Perry

Gregory D. Perry

EVP & CFO

ImmunoGen Office Locations

ImmunoGen has offices in Waltham, Norwood, Brentwood
Waltham, US
Brentwood, US
Norwood, US

ImmunoGen Metrics

ImmunoGen Summary

Market capitalization

$309.3 m

Closing share price

$3.7
ImmunoGen's current market capitalization is $309.3 m.

ImmunoGen Financials

ImmunoGen's revenue is $60 m in FY, 2016 which is a 29.9% decrease from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

$59.9 m$85.5 m$60 m

Revenue growth, %

42.8%(29.9%)

Operating expense total

$131.4 m$140 m$185 m

EBIT

($71.5 m)($54.5 m)($125 m)

Net Income

($71.4 m)($60.7 m)($144.8 m)

Operating cash flow

($52.7 m)$135.8 m($33.1 m)

ImmunoGen Market Value History

ImmunoGen Online Presence

ImmunoGen Company Life

You may also be interested in